A House investigation has concluded that the Food and Drug Administration (FDA) “collaborated” with biotechnology company Biogen on the approval of its Alzheimer’s drug Aduhelm. Indeed, as 2022 comes to a close, American taxpayers are reminded yet again of the inappropriate and dishonest manner in which the FDA—the agency funded by taxpayers to ensure the … Continue reading Congressional Report: FDA Inappropriately “Collaborated” with Biogen